American Society of Hematology

Figure 2.

$IRC-assessed change in tumor volume from baseline. (A) Patients with EZH2mut follicular lymphoma. (B) Patients with EZH2WT follicular lymphoma. Tumor responses were not estimable, missing, or unknown in five patients in the EZH2WT cohort. Dashed red lines represent thresholds for progressive disease (≥50% increase in tumor volume) and partial response (≥50% reduction in tumor volume). The shaded area represents tumor volume changes that correspond to stable disease (<50% increase or decrease in tumor volume). IRC, independent radiology committee. Reprinted from The Lancet Oncology, Vol 21, Morschhauser F et al, Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial, 1433-1442, 2020, with permission from Elsevier.$

IRC-assessed change in tumor volume from baseline. (A) Patients with EZH2mut follicular lymphoma. (B) Patients with EZH2WT follicular lymphoma. Tumor responses were not estimable, missing, or unknown in five patients in the EZH2WT cohort. Dashed red lines represent thresholds for progressive disease (≥50% increase in tumor volume) and partial response (≥50% reduction in tumor volume). The shaded area represents tumor volume changes that correspond to stable disease (<50% increase or decrease in tumor volume). IRC, independent radiology committee. Reprinted from The Lancet Oncology, Vol 21, Morschhauser F et al, Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial, 1433-1442, 2020, with permission from Elsevier.

This Feature Is Available To Subscribers Only